Editas Medicine, Inc. (EDIT)
| Market Cap | 2.76B |
| Revenue (ttm) | 90.73M |
| Net Income (ttm) | -115.98M |
| Shares Out | 58.61M |
| EPS (ttm) | -1.98 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $43.86 |
| Previous Close | $44.76 |
| Change ($) | -0.90 |
| Change (%) | -2.01% |
| Day's Open | 45.00 |
| Day's Range | 42.33 - 46.24 |
| Day's Volume | 3,043,288 |
| 52-Week Range | 14.01 - 99.95 |
With the trading day more than halfway over, the broad markets recovered slightly from Thursday's downturn, with the exception of the Dow Jones industrial average.
ARK Investment Management – or ARK Invest, as it usually styles itself – had a great 2020. ARK Innovation ETF (ARKK), the firm's flagship fund, returned more than 150% last year.
Editas (EDIT) reports wider-than-expected loss in the fourth quarter of 2020 while revenues beat estimates. Pipeline development a key focus for the company.
After a huge run-up in valuation, investors are a little spooked.
Turnover at the top of a company can be troubling. But it can sometimes be a good thing.
CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on T...
Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In a field that's becoming more crowded, what will set Editas apart?
On Editas' (EDIT) fourth-quarter earnings call, investor focus will be on the company's progress with the development of its CRISPR-based experimental candidate, EDIT-101.
Editas Medicine (EDIT) closed the most recent trading day at $57.94, moving +1.35% from the previous trading session.
As more young investors take up day trading, I have a recipe for long-term wealth creation
As more young investors take up day trading, I have an important recipe for long-term wealth creation.
Investors reacted negatively to a major deal announced by Editas' former partner with another gene-editing biotech.
In the latest trading session, Editas Medicine (EDIT) closed at $63.18, marking a +1.64% move from the previous day.
Gene-editing technology is used to insert, edit, or delete a gene from an organism's genome, and shows promise in treating medical conditions ranging from cancer to rare genetic conditions. Ou...
Could this maverick biotech discover the cure for several debilitating rare diseases?
In the latest trading session, Editas Medicine (EDIT) closed at $65.47, marking a -0.44% move from the previous day.
Editas Medicine, a biotechnology company focused on developing treatments using gene editing technology, has plunged by 13% over the last 5 trading days, after the company stated its plans to ...
It's a big bet but not a big gamble.
With a nest egg this sizable, you'll need to find more than one place to put your money so it keeps growing.
Sana Biotechnology Seeks $150 Million U.S. IPO
There are only a handful of large, well-established gene editors with robust and mature therapy pipelines in the world today. Of those, one that stands out is a $4.8 billion biotechnology comp...
All four biotechs announced the pricing of stock offerings.
CAMBRIDGE, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced the pricing of an underwritten offering of 3,500,000 s...
Among the public companies that made the BioSpace list of the top up and coming life sciences firms in 2019 and 2020, the majority have seen gains in their share prices. Given this metric, inv...
CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced that it intends to offer and sell 3,500,000 shares of ...
Editas' (EDIT) lead candidate EDIT-101, that employs CRISPR gene editing to treat LCA10, holds potential. The company is also developing EDIT-301 for treating SCD.
Commentary from Ark Invest: We share weekly commentaries with investors on stocks in our strategies that have appreciated or dropped more than 15% in a day during the course of the week.
Editas Medicine (EDIT) closed at $76.14 in the latest trading session, marking a +0.29% move from the prior day.
Between these seven genetic editing pioneers, you have the widest exposure to the biggest scientific breakthrough of the century. The post 7 CRISPR Stocks for the Future of Medicine appeared f...
Despite a stellar 4x rise since the March 23 lows of last year, at the current price of around $73 per share we believe Editas Medicine, a biotechnology company focused on developing treatment...
Just because they did it in 2020 doesn't mean they won't outrun the market again in the new year.
The FDA clears the initiation of the safety phase of Editas' (EDIT) early-stage study on investigational gene-editing therapy EDIT-301 for treating sickle cell disease. Shares down.
Gene editing has emerged as a promising biotech theme. The technology is used to insert, edit, or delete a gene from an organism's genome, helping to replace the defective genes responsible fo...
Details progress on ocular programs, including EDIT-101 Phase 1/2 BRILLIANCE trial updates
EDIT-301 is in development as a best-in-class, durable medicine for people living with sickle cell disease EDIT-301 is in development as a best-in-class, durable medicine for people living wit...
CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that its Chief Scientific Officer, Charles Albright,...
A leading portfolio manager recently told Bloomberg Television that gene-editing companies may turn out to be better investment opportunities than Tesla Inc. (NASDAQ:TSLA).
Intellia Therapeutics offered an update Thursday for its gene-editing programs, helping boost genetics stocks Crispr Therapeutics, Editas Medicine, Fate Therapeutics and Beam Therapeutics. The...
Over halfway through the trading day on Thursday, and the broad markets are making a run into the afternoon.
Here we discuss three booming technological developments in the biotech sector, which can capture investor attention in 2021
Clinical trial readouts this year could cause these closely watched biotech stocks to explode overnight.
CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will present a company overview at the 39th ...
Here we discuss five biotech stocks - EDIT, VRTX, NTLA, CBAY, MRNS - that could prove to be great investments in the long run.
Big drugmakers could be attracted to these smaller players with promising pipelines.
The gene-editing stocks are being pulled down by a broader biotech sell-off.
Crispr Therapeutics, Editas Medicine and Intellia Therapeutics were ablaze Monday as all three genetics stocks touched highs. Uniqure stock fell on a clinical hold for its gene therapy test.
Shares of Editas Medicine, a genome editing company that utilizes CRISPR technology, soared as much as 50% to new all-time highs on Monday. There was no official news from the company to expla...
About EDIT
Editas Medicine operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary genome editing platform based on CRISPR technology, which includes CRISPR/Cas9, CRISPR/Cas12a, and engineered forms of both of these CRISPR systems to target genetically addressable diseases and therapeutic areas. It also develops EDIT-101, which is in Phase 1/2 clinical trial for the treatment of Leber Congenital Amaurosis type 10, a gene... [Read more...]
| Industry Biotechnology | IPO Date Feb 3, 2016 |
| CEO Cynthia Collins | Country United States |
| Stock Exchange NASDAQ | Ticker Symbol EDIT |
Financial Performance
In 2020, EDIT's revenue was $90.73 million, an increase of 341.93% compared to the previous year's $20.53 million. Losses were -$115.98 million, -13.29% less than in 2019.
Analyst Forecasts
According to 12 analysts, the average rating for EDIT stock is "Buy." The 12-month stock price forecast is 54.83, which is an increase of 25.01% from the latest price.